Table 1 Baseline characteristics of the study population (N = 80)
Characteristics | Total cohort (N = 80) | Gefitinib (N = 16) | Afatinib (N = 30) | Erlotinib (N = 34) | P values |
|---|---|---|---|---|---|
Age, y | 64.5 (57.2–70.5) | 67.0 (62.5–79.0) | 60.5 (54.3–66.0) | 65.0 (56.8–69.5) | 0.019 |
Male sex | 34 (43) | 8 (50) | 11 (37) | 15 (44) | 0.663 |
ECOG | Â | Â | Â | Â | Â |
   0–1 | 74 (93) | 14 (88) | 27 (90) | 33 (97) | 0.393 |
   ≥2 | 6 (8) | 2 (13) | 3 (10) | 1 (3) |  |
Smoking status | Â | Â | Â | Â | Â |
   Current or former smoker | 23 (29) | 6 (38) | 8 (27) | 9 (27) | 0.688 |
   Never-smoker | 57 (71) | 10 (63) | 22 (73) | 25 (74) |  |
Stage | Â | Â | Â | Â | Â |
   IIIB/IV | 73 (91) | 14 (88) | 27 (90) | 32 (94) | 0.708 |
   Post-operative recurrence | 7 (9) | 2 (13) | 3 (10) | 2 (6) |  |
EGFR mutation | Â | Â | Â | Â | Â |
   L858R | 35 (44) | 9 (56) | 11 (37) | 15 (44) | 0.095 |
   Exon 19 deletion | 41 (51) | 7 (44) | 15 (50) | 19 (56) |  |
   Others†| 4 (5) | 0 (0) | 4 (13) | 0 (0) |  |
Initial presentation | Â | Â | Â | Â | Â |
   Malignant pleural effusion | 25 (31) | 5 (31) | 8 (27) | 12 (35) | 0.759 |
   Malignant pericardial effusion | 3 (4) | 0 (0) | 1 (3) | 2 (6) | 0.587 |
   Brain metastasis | 29 (36) | 2 (13) | 8 (27) | 19 (56) | 0.005 |
   Liver metastasis | 7 (9) | 2 (13) | 1 (3) | 4 (12) | 0.412 |
   Bone metastasis | 40 (50) | 7 (44) | 13 (43) | 20 (59) | 0.398 |
Best response to EGFR TKI | Â | Â | Â | Â | Â |
   Partial response | 55 (69) | 9 (56) | 24 (80) | 22 (65) | 0.522 |
   Stable disease | 21 (26) | 6 (38) | 5 (17) | 10 (29) |  |
   Progressive disease | 4 (5) | 1 (6) | 1 (3) | 2 (6) |  |
Time to progression, mo‡ | 13.8 (8.2–21.6) | 14.3 (9.8–25.2) | 15.8 (7.2–24.2) | 13.3 (7.3–19.0) | 0.429 |
Duration of first-line TKI, mo§ | 18.5 (11.1–26.1) | 22.7 (12.5–31.2) | 21.0 (12.0–28.7) | 15.1 (9.0–23.6) | 0.144 |
Overall survival, mo¶ | 36.2 (23.3–54.9) | 49.5 (35.5–56.1) | 37.5 (23.6–58.1) | 33.0 (20.5–40.9) | 0.043 |